End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
20.52 CNY | -0.58% | +1.94% | -11.40% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The stock, which is currently worth 2023 to 0.55 times its sales, is clearly overvalued in comparison with peers.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-11.40% | 1.7B | C- | ||
-30.14% | 15.18B | B- | ||
-41.56% | 9.47B | B | ||
-10.75% | 6.15B | C+ | ||
+6.59% | 6.04B | C | ||
-38.44% | 5.44B | B | ||
+2.34% | 4.86B | D- | ||
+50.00% | 4.23B | - | C | |
-12.78% | 3.55B | B | ||
-10.36% | 3.51B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 002727 Stock
- Ratings Yixintang Pharmaceutical Group Co., Ltd.